Do you test "rescue" drugs as well?

Yes, many of the 13 anticancer drugs we provide predictions for are used for rescue therapy. The drugs we test against are: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Tanovea, Chlorambucil, Mechlorethamine, Lomustine, Prednisone, Cyclophosphamide, Melphalan, and Dexamethasone.

Other Questions

Back to Help Center

What type of sample is needed – just aspirates and a typical flow sample?

We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).

How long can the media tubes be outside of that temperature before going bad?

We will send you another batch of media tubes you could use. Please make the supply request on the Vet Portal > Request Supplies page.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

What is included in the ImpriMed Immunoprofile service?

The ImpriMed Immunoprofile service includes both our Flow Cytometry and PARR reports. These comprehensive results can be used to detect the presence of lymphoma or leukemia and determine the disease subtype.

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.